| Original language | English (US) |
|---|---|
| Pages (from-to) | 688-689 |
| Number of pages | 2 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 87 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2022 |
Funding
Dr Chovatiya has served as an advisory board member, consultant, and/or investigator for AbbVie, Arcutis, Arena, Dermavant, Incyte, National Eczema Association, Pfizer, Regeneron, and Sanofi-Genzyme and speaker for AbbVie, Incyte, Regeneron, Sanofi-Genzyme, and UCB. Dr Silverberg reports personal fees from AbbVie, Afyx, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, and Sanofi-Genzyme; the institution received grants from Galderma.
Keywords
- atopic dermatitis
- burden
- eczema
- heterogeneity
- longitudinal
- persistence
ASJC Scopus subject areas
- Dermatology